Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 4, pp 455–460 | Cite as

Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats

  • Sherif Y. SaadEmail author
  • Maha M. Arafah
  • Tawfeeg A. Najjar
Original Article



Inflammation and oxidative stress are important events among the plethora of mechanisms involved in cisplatin (CDDP)-induced nephrotoxicity. The aim of this study was to evaluate the effect of mycophenolate mofetil (MMF), an immunosuppressive, in the protection against CDDP-induced renal dysfunction.


Rats were divided into four groups; untreated-control group, CDDP-treated group (7 mg/kg, single intraperitoneal dose), MMF-treated group (40 mg/kg/day orally for 5 successive days) and the fourth group was treated with both drugs and MMF treatment was started 1 day prior to CDDP administration. Nephrotoxicity was assessed 7 days after the CDDP treatment by measuring serum indices of nephrotoxicity, kidney weight as a percentage of total body weight, kidney’s tissue peroxidative alterations and total nitrate/nitrite concentration (NOx) and the results were confirmed histopathologically.


Rats treated with CDDP showed marked nephrotoxicity as evidenced from the significant increase in serum creatinine and urea levels and decrease in serum calcium and albumin levels. Kidneys of CDDP-treated rats showed significant increases in kidney weight and malondialdehyde (MDA) production level and decreases in total NOx concentration, glutathione peroxidase (GPx) activity and reduced glutathione (GSH) content levels. Histopathological assessment of kidneys of CDDP-treated rats revealed extensive tubular necrosis with “sloughing off” of the renal tubular lining cells, intratubular hyaline casts and mononuclear cell infiltration. Treatment with MMF significantly protected the rats against CDDP-induced nephrotoxicity. The rise in serum creatinine and urea levels, kidney weight and kidney tissue MDA production, depletion of “endogenous antioxidant reserve” including GPx activity and reduced GSH content levels and the deleterious histopathological changes induced by CDDP treatment were significantly mitigated by MMF treatment.


MMF treatment dramatically ameliorates CDDP-induced renal dysfunction.


Cisplatin Mycophenolate mofetil Nephrotoxicity Rats 


  1. 1.
    Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, Rabb H (2006) A pathophysiologic role for T lymphocytes in murine acute Cisplatin nephrotoxicity. J Am Soc Nephrol 17:765–774PubMedCrossRefGoogle Scholar
  2. 2.
    Taguchi T, Nazneen A, Abid MR, Razzaque MS (2005) Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 148:107–121PubMedCrossRefGoogle Scholar
  3. 3.
    Jo SK, Cho WY, Sung SA, Kim HK, Won NH (2005) MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67:458–466PubMedCrossRefGoogle Scholar
  4. 4.
    Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK (2003) Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 142:178–186PubMedCrossRefGoogle Scholar
  5. 5.
    Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J (2004) Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 4:20PubMedCrossRefGoogle Scholar
  6. 6.
    Ikari A, Nagatani Y, Tsukimoto M, Harada H, Miwa M, Takagi K (2005) Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 1717:109–117PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H, Iida M (2003) Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 285:F208–218PubMedGoogle Scholar
  8. 8.
    Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. Clin Invest 110:835–842CrossRefGoogle Scholar
  9. 9.
    Banas B, Luckow B, Moller M, Klier C, Nelson PJ, Schadde E, Brigl M, Halevy D, Thofer HH, Reinhart B, Schlondorff D (1999) Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 10:2314–2322PubMedGoogle Scholar
  10. 10.
    Rovin B, Phan L (1998) Chemotactic factors and renal inflammation. Am J Kidney Dis 31:1065–1084PubMedGoogle Scholar
  11. 11.
    Mele TS, Halloran PF (2000) The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 47:215–245PubMedCrossRefGoogle Scholar
  12. 12.
    Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85–118PubMedCrossRefGoogle Scholar
  13. 13.
    Engl T, Makarević J, Relja B, Natsheh I, Müller I, BeeckenWD, Jonas D, Blaheta RA (2005) Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 5:4PubMedCrossRefGoogle Scholar
  14. 14.
    Bonsnes RW, Taussky HN (1945) On the colorimetric determination of creatinine by Jaffe reaction. J Biol Chem 158:581–591Google Scholar
  15. 15.
    Hallett CJ, Cook JG (1971) Reduced nicotinamide adenine dinucleotide-coupled reaction for emergency blood urea estimation. Clin Chim Acta 35:33–37PubMedCrossRefGoogle Scholar
  16. 16.
    Wrenn HT, Feichtmeir TV (1956) The quantitation of albumin based on dye linear binding capacity. Am J Clin Pathol 26:960–968PubMedGoogle Scholar
  17. 17.
    Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5:62–71PubMedCrossRefGoogle Scholar
  18. 18.
    Ohkawa H, Ohishi N, Yagi K (1979) Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRefGoogle Scholar
  19. 19.
    Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158–169PubMedGoogle Scholar
  20. 20.
    Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–71PubMedCrossRefGoogle Scholar
  21. 21.
    Links M, Lewis C (1999) Chemoprotectants. A review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293–308PubMedCrossRefGoogle Scholar
  22. 22.
    Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480PubMedCrossRefGoogle Scholar
  23. 23.
    Kintzel PE (2001) Anticancer drugs-induced kidney disorders. Drug saf 24:19–28PubMedCrossRefGoogle Scholar
  24. 24.
    Saad SY, Najjar TAO, Alashari M (2004) Role of non-selective adenosine receptor blockade and phosphodiestrase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 31:862–867PubMedCrossRefGoogle Scholar
  25. 25.
    Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA inter-strand cross-link. Science 270:1842–1845PubMedCrossRefGoogle Scholar
  26. 26.
    Ueda N, Kaushal GP, Shah SV (2000) Apoptotic mechanisms in acute renal failure. Am J Med 108:403–415PubMedCrossRefGoogle Scholar
  27. 27.
    Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166–174PubMedCrossRefGoogle Scholar
  28. 28.
    Haddad JJ (2002) The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK(p38)-dependent regulation of pro-inflammatory cytokine production. Biochem Pharmacol 63:305–320PubMedCrossRefGoogle Scholar
  29. 29.
    Tapia E, Franco M, Sanchez-Lozada LG, Soto V, Avila-Casado C, Santamaria J, Quiroz Y, Rodriguez-Iturbe B, Herrera-Acosta J (2003) Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 63:994–1002PubMedCrossRefGoogle Scholar
  30. 30.
    Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ (2001) Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59:2222–2232PubMedGoogle Scholar
  31. 31.
    Lui SL, Chan LYY, Zhang XH, Zhu W, Chan TM, Fung PCW, Lai KN (2001) Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury. Nephrol Dial Transplant 16:1577–1582PubMedCrossRefGoogle Scholar
  32. 32.
    Senda M, Delustro B, Eugui E, Natsumeda Y (1995) Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 60:1143–1148PubMedCrossRefGoogle Scholar
  33. 33.
    Nieto E, Escudero E, Navarro E, Yanez-Mo M, Martin A, Perez de Lema G, Sanchez-Madrid F, Mampaso F (2002) Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis. J Am Soc Nephrol 13:937–945PubMedGoogle Scholar
  34. 34.
    Iguchi S, Nishi S, Ikegame M, Hoshi K, Yoshizawa T, Kawashima H, Arakawa M, Ozawa H, Gejyo F (2004) Expression of osteopontin in cisplatin-induced tubular injury. Nephron Exp Nephrol 97:e96–105PubMedCrossRefGoogle Scholar
  35. 35.
    Wang W, Moschan L (1999) Mycophenolic acid inhibits PDGF-induced osteopontin expression in rat mesangial cells. Transplant Proc 31:1176–1177PubMedCrossRefGoogle Scholar
  36. 36.
    Graciano ML, Cavaglieri Rde C, Delle H, Dominguez WV, Casarini DE, Malheiros DM, Noronha IL (2004) Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 15:1805–1815PubMedCrossRefGoogle Scholar
  37. 37.
    Ardiles LG, Ehrenfeld P, Quiroz Y, Rodriguez-Iturbe B, Herrera-Acosta J, Mezzano S, Figueroa CD (2002) Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats. Kidney Blood Press Res 25:289–295PubMedCrossRefGoogle Scholar
  38. 38.
    Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M (2000) Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51–61PubMedCrossRefGoogle Scholar
  39. 39.
    Gilbert RE, Kelly DJ, Mckay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59:1324–1332PubMedCrossRefGoogle Scholar
  40. 40.
    Park J, Ha H, Seo J, Kim MS, Kim HJ, Huh KH, Park K, Kim YS (2004) Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and nitrogen-activated protein kinase activation in rat vascular smooth muscle cells. Am J transplant 4:1982–1990PubMedCrossRefGoogle Scholar
  41. 41.
    Ludewig D, Kosmehl H, Sommer M, Bohmer FD, Stein G (2000) PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299:97–103PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Sherif Y. Saad
    • 1
    Email author
  • Maha M. Arafah
    • 2
  • Tawfeeg A. Najjar
    • 1
  1. 1.Department of Clinical PharmacyCollege of Pharmacy, King Saud UniversityRiyadhSaudi Arabia
  2. 2.Department of pathologyCollege of Medicine, King Saud UniversityRiyadhSaudi Arabia

Personalised recommendations